OMARINI, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.346
EU - Europa 5.655
AS - Asia 5.605
SA - Sud America 838
AF - Africa 172
Continente sconosciuto - Info sul continente non disponibili 155
OC - Oceania 33
Totale 23.804
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.061
IT - Italia 1.710
SG - Singapore 1.582
CN - Cina 1.339
GB - Regno Unito 974
IE - Irlanda 833
VN - Vietnam 646
HK - Hong Kong 628
BR - Brasile 598
DE - Germania 513
BD - Bangladesh 371
SE - Svezia 368
FR - Francia 254
RU - Federazione Russa 208
FI - Finlandia 204
IN - India 178
CA - Canada 155
ID - Indonesia 150
KR - Corea 145
UA - Ucraina 113
TR - Turchia 94
AR - Argentina 80
JP - Giappone 71
NL - Olanda 64
BG - Bulgaria 63
IQ - Iraq 63
MX - Messico 59
PL - Polonia 51
LT - Lituania 46
CO - Colombia 45
ES - Italia 45
TW - Taiwan 41
CL - Cile 39
ZA - Sudafrica 35
EG - Egitto 34
PK - Pakistan 34
MY - Malesia 32
AU - Australia 30
BE - Belgio 30
CZ - Repubblica Ceca 30
EC - Ecuador 30
AE - Emirati Arabi Uniti 27
AT - Austria 25
IR - Iran 23
MA - Marocco 23
VE - Venezuela 23
SA - Arabia Saudita 22
NP - Nepal 19
JO - Giordania 18
KE - Kenya 18
RO - Romania 18
TH - Thailandia 16
PH - Filippine 15
CH - Svizzera 13
JM - Giamaica 13
CR - Costa Rica 12
MD - Moldavia 12
TN - Tunisia 11
UZ - Uzbekistan 11
AZ - Azerbaigian 10
EU - Europa 10
PY - Paraguay 10
SY - Repubblica araba siriana 10
DO - Repubblica Dominicana 9
HN - Honduras 9
HU - Ungheria 9
IL - Israele 9
RS - Serbia 8
BH - Bahrain 7
DZ - Algeria 7
GR - Grecia 7
NG - Nigeria 7
AL - Albania 6
PE - Perù 6
PT - Portogallo 6
TT - Trinidad e Tobago 6
AO - Angola 5
CI - Costa d'Avorio 5
ET - Etiopia 5
GH - Ghana 5
HR - Croazia 5
KG - Kirghizistan 5
LB - Libano 5
MT - Malta 5
SK - Slovacchia (Repubblica Slovacca) 5
BO - Bolivia 4
CY - Cipro 4
DK - Danimarca 4
EE - Estonia 4
GA - Gabon 4
LV - Lettonia 4
NI - Nicaragua 4
NO - Norvegia 4
PS - Palestinian Territory 4
SI - Slovenia 4
SV - El Salvador 4
IS - Islanda 3
KH - Cambogia 3
KZ - Kazakistan 3
LK - Sri Lanka 3
Totale 23.602
Salva come PNG Salva come JPEG
Città #
Ashburn 1.476
Santa Clara 1.056
Singapore 1.037
Dublin 828
San Jose 721
Fairfield 636
Hong Kong 601
Chandler 592
Dallas 497
Council Bluffs 429
Southend 420
Hefei 337
Houston 313
Woodbridge 295
Beijing 285
Seattle 261
Nyköping 259
Wilmington 242
New York 231
Ann Arbor 227
Dearborn 215
London 213
Los Angeles 208
Ho Chi Minh City 204
Cambridge 176
Helsinki 166
Modena 159
Milan 157
Jacksonville 150
The Dalles 150
Hanoi 144
Chicago 136
Seoul 135
Jakarta 111
Munich 107
Shanghai 96
Rome 93
Lauterbourg 89
Bologna 84
San Diego 74
Moscow 73
Fremont 62
Buffalo 61
Sofia 61
Princeton 60
Columbus 59
Frankfurt am Main 58
Orem 53
Redwood City 52
São Paulo 52
Tokyo 51
Phoenix 48
Eugene 44
Dong Ket 41
Salt Lake City 40
Warsaw 39
Baghdad 38
Izmir 37
Toronto 37
Guangzhou 34
Bremen 33
Brooklyn 33
Enfield 32
Parma 32
Reggio Emilia 30
Mumbai 29
Tampa 28
Atlanta 27
Elk Grove Village 26
Portsmouth 26
San Giuliano Milanese 26
Da Nang 25
Falls Church 25
Montreal 25
Paris 25
Denver 24
Redondo Beach 24
Boardman 23
Lawrence 22
Nuremberg 22
Asyut 21
Brussels 21
Santiago 21
Miami 20
Chennai 19
Haiphong 19
Naples 19
Amsterdam 18
Dhaka 18
Florence 18
Johannesburg 18
Kent 18
Mexico City 18
Genoa 17
Palermo 17
Poplar 17
Turku 17
Brasília 16
Des Moines 16
Newark 16
Totale 15.511
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 651
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 474
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 448
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 417
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 412
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 410
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 409
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 399
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 390
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 388
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 381
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 381
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 379
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 376
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 375
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 370
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 368
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 362
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 347
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 342
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 336
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 336
Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP guidelines: a single institution analysis. 334
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 332
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 328
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 327
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 327
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 327
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 322
Immune characterization of breast cancer metastases: prognostic implications. 321
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 320
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 320
PROFILO MUTAZIONALE DI TUMORI MAMMARI HER2 POSITIVI TRATTATI CON CHEMIOTERAPIA NEOADIUVANTE​ 314
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 312
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 312
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 311
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 301
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 294
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 294
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 290
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 288
Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery. 285
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 281
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis 279
Adjuvant exemestane or tamoxifen plus ovarian suppression in premenopausal women: single institution analysis 277
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 277
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges 272
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 268
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 265
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 265
The role of exosomes in breast cancer diagnosis 260
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis 257
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. 253
TDM-1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis 249
Breast cancer follow-up: a national survey of current clinical practice by the centers of Italian Oncological Group of Clinical Research (GOIRC). 247
Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. 243
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. 236
Lapatinib and renal impairment: a case report 235
Next Generation Sequencing (NGS): a possible game changer in metastatic breast cancer 234
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature 234
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 230
Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it! 229
EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project 226
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 225
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 222
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affectclinical outcome of metastatic breast cancer patients 221
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 217
Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study. 217
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 215
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 203
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib 191
Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist 182
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes 181
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study 178
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer (HR+/HER2- mBC): regulatory aspects and clinical impact in Europe 174
TDM-1 efficacy in trastuzumabpertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis 172
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. 159
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 159
Atezolizumab-Related Sarcoidosis-Like Reaction in Early Breast Cancer Patient: Know It To Diagnose It: A Case Report with Review of the Literature 158
Pneumonitis and pulmonary fibrosis associated with breast cancer treatments 154
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 111
Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer 105
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials. BMC Cancer 33
Totale 23.804
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.649
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.649
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.027 0 0 0 58 51 110 63 71 131 126 251 166
2022/20232.647 191 266 146 186 174 202 47 156 960 50 168 101
2023/20241.429 75 65 102 138 175 130 160 211 54 64 102 153
2024/20254.164 141 53 127 268 814 592 319 257 410 286 335 562
2025/20268.506 567 251 924 798 1.108 510 1.047 441 806 789 712 553
2026/20271.529 256 418 617 238 0 0 0 0 0 0 0 0
Totale 23.804